You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Human Neural Cell Exosomes as a Therapeutic Treatment for Stroke

    SBC: ARUNA BIO, INC.            Topic: NINDS

    Project Summary Cytoprotective and restorative treatments for acute ischemic stroke (AIS) is a major unmet medical need. The current standard of care for stroke patients is centered on recanalization efforts to restore cerebral perfusion through the administration of tissue plasminogen activator (tPA) or mechanical thrombectomy. However, despite a recent extension of recanalization treatment windo ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas

    SBC: BIOMIMETIX JV LLC            Topic: NCI

    PROJECT SUMMARY/ABSTRACT A randomized, proof-of-concept, Phase 2 clinical trial of a new class of redox-active pharmaceutical is proposed in 160 subjects undergoing primary treatment for high-grade glioma (WHO grade III and IV). Under a prior Phase II SBIR, a Phase 1 clinical trial has been completed with establishment of the recommended dose being used for this Phase 2 clinical trial. This projec ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective,Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage

    SBC: NEUROP, INC.            Topic: 102

    Abstract Subarachnoid hemorrhageSAHremains a serious source of neurological morbiditywith approximatelycases reported in the US each yearDespite advances in treating the initial and subsequent bleedspost surgical clipping of the aneurysm is associated with a significant risk of delayed cerebral ischemiaDCIThese events typically occur within the firstdays after aneurysmal rupture and DCI remains th ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. High-resolution Non-cryogenic Magnetoencephalography: Systems-Level Integration

    SBC: QUSPIN INC.            Topic: NIMH

    Abstract Magnetoencephalography (MEG) is an important functional neuroimaging technique that provides an excellent combination of high spatial and temporal resolution. At present, MEG scanners are handicapped by cost and complexity imposed by cryogenically cooled superconducting sensor technology. In our recently completed Phase II project, we developed new noncryogenic optical sensors that are su ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. TITER ON CHIP ALTERNATIVE TO SRID FOR INFLUENZA VACCINE POTENCY DETERMINATION

    SBC: INDEVR, INC.            Topic: NIAID

    DESCRIPTION provided by applicant It is widely acknowledged that for split vaccines potency determination is often a rate limiting step The FDA approved andquot gold standardandquot potency assay for influenza hemagglutinin HA protein based vaccines is single radial immunodiffusion SRID SRID is a time and labor intensive assay often requiring days to complete and a minimum of hou ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. A wearable high-density MEG system with uOPMs

    SBC: FieldLine Inc.            Topic: 101

    Abstract In this Phase II project, we will build a complete high-density wearable full-head MEG system using our micro-OPM sensors and to cross-validate our system against current SQUID-based MEG systems. A complete system consists of (1) the sensor system - an array of 128 sensors and their control electronics that performs synchronous data collection and control; (2) a MEG cap that conforms to t ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme

    SBC: NEUROP, INC.            Topic: 102

    DESCRIPTION provided by applicant Cerebral ischemia is a major cause of death and long term disability with high accompanying social and medical costs Approximately Americans suffer a stroke each year at an estimated annual cost of $ B American Heart Association Heart Disease and Stroke Statistics Update Substantial preclinical data support the use of NMDA receptor antago ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Advanced therapeutic for Parkinson's Disease

    SBC: Inhibikase Therapeutics, Inc.            Topic: 105

    Parkinson s DiseasePDis a progressive neurodegenerative disorder that affectsmillion patient in the U Sannually andtomillion people worldwidePD is characterized by disorders of movementwhich are caused by the progressive loss of dopamine neurons in the substantia nigra pars compactaSNpcand autonomic dysfunctionanxietydepressionsleep disorders and cognitive impairment that are due to the degenerati ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Advanced therapeutic for Parkinson's Disease

    SBC: Inhibikase Therapeutics, Inc.            Topic: 999

    Parkinsonandapos;s Disease (PD) is a progressive neurodegenerative disorder that affects ≈1 million patient in the U.S. annually and 7 to 10 million people worldwide. PD is characterized by disorders of movement, which are caused by the progressive loss of dopamine neurons in the substantia nigra pars compacta (SNpc), and autonomic dysfunction, anxiety, depression, sleep disorders and cognitive ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government